Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.15 USD

76.15
421,444

+0.21 (0.28%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

Investors are upbeat about Haemonetics (HAE) owing to impressive Plasma and Hospital business performance, with continued strength in the Hemostasis Management product line.

Nilanjan Banerjee headshot

4 Low-Beta Stocks to Buy to Endure Market Volatility

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Haemonetics (HAE), The Kroger Co. (KR), JOYY (YY) and Novo Nordisk (NVO) are poised to gain.

AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.

Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays

Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.

Thermo Fisher (TMO) Partners With ArsenalBio for Cancer R&D

Thermo Fisher's (TMO) latest collaboration with ArsenalBio supports the latter's clinical manufacturing of autologous T-cell therapies for advanced cancer treatment.

Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch

Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.

Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion

Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.

Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF

Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.

Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe

Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.

Abbott's (ABT) CardioMEMS Favors Heart Failure Management

Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.

HAE vs. SYK: Which Stock Should Value Investors Buy Now?

HAE vs. SYK: Which Stock Is the Better Value Option?

Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs

The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.

Smith & Nephew's (SNN) CIT Technology Favored by New Study

Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.

Syneos Health (SYNH) Partners With KX for Data-Driven Insights

Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.

Henry Schein (HSIC) Bolsters Dental Practices With AI Tools

Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.

Quest Diagnostics (DGX) Acquires Northern Light Laboratory

Quest Diagnostics (DGX) now offers professional laboratory management services for nine of Northern Light Health's hospital laboratories.

NuVasive's (NUVA) Precice System Cleared for Pediatric Patients

NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.

Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes

Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).

Quest Diagnostics (DGX) Updates Its Strategic Focus, LT Growth

Quest Diagnostics (DGX) is building strong platforms to focus on high-growth areas like molecular genomics and oncology.

Here's Why You Should Retain Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX), led by impressive value-added acquisitions.

Bruker (BRKR) Receives 1.2 GHz NMR System Orders From the UK

Bruker (BRKR) extends support to the expansion efforts of the UK Science community by providing 1.2 GHz Avance NMR spectrometers.

Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2

Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.

Medtronic's (MDT) Affera Ablation System Gets CE Mark

Medtronic's (MDT) Affera Mapping and Ablation System is intended to treat atrial arrhythmias.

Abbott (ABT) Diabetes Arm Growth Robust Amid Macroeconomic Woes

Abbott (ABT) currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales, to be in the high-single digits in 2023.